IPSEN (OTCMKTS:IPSEY) Shares Down 8.3% – Here’s Why

IPSEN (OTCMKTS:IPSEY)’s share price dropped 8.3% on Monday . The stock traded as low as $42.4080 and last traded at $42.4080. 241 shares changed hands during trading, a decline of 87% from the average daily volume of 1,899 shares. The stock had previously closed at $46.2280.

Analysts Set New Price Targets

A number of brokerages recently issued reports on IPSEY. HC Wainwright reissued a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Barclays raised shares of IPSEN from a “strong sell” rating to a “hold” rating in a research note on Thursday, September 17th. Zacks Research upgraded IPSEN to a “hold” rating in a research note on Friday, May 29th. Finally, Jefferies Financial Group lowered shares of IPSEN from a “hold” rating to a “moderate sell” rating in a research note on Sunday, August 2nd. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, IPSEN currently has a consensus rating of “Hold”.

IPSEN Stock Performance

The firm’s fifty day moving average price is $46.24 and its 200-day moving average price is $46.65.

IPSEN Company Profile

Ipsen SA is a France-based biopharmaceutical company that develops and commercializes specialty medicines for serious diseases. Its primary focus areas are oncology, rare diseases and neuroscience, with research and development activities aimed at addressing conditions that often have limited treatment options.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected neurological and muscular conditions, and oncology treatments including Cabometyx and Onivyde.